💨 Abstract

Foreign pharmaceutical companies have complained to India's health ministry that the Drug Controller General of India (DCGI) is not allowing the launch of breakthrough drugs without local clinical trials, despite rules allowing a waiver for certain categories of drugs approved in select countries. The DCGI has yet to approve any drug with the waiver, despite applications by multiple foreign drugmakers for marketing approval of their life-saving and key therapies.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖